Monmouth Junction-based CytoSorbents Corp. on Monday announced the promotion of Chief Operating Officer Vincent Capponi to president and COO, effective immediately.
“Having worked closely with Vince for over a dozen years, much of the success of CytoSorbents to date is a testament to his many outstanding contributions in all aspects of the company,” Chief Executive Officer Dr. Phillip Chan said.
In his 18 years with the company, Capponi helped to manage daily operations with a focus on manufacturing, engineering, regulatory, clinical studies, and new product development and research. He played a pivotal role in the development and scale-up of the polymer technology from an R&D phase to commercial production, helped to spearhead the first clinical trial in septic shock patients in Germany, and drove European Union CE Mark (a type of certification) designation for CytoSorb as an extracorporeal cytokine adsorber to treat cytokine storm in many illnesses.
Capponi further expanded market access for CytoSorb by successfully navigating three CE Mark label expansions, including the removal of myoglobin (rhabdomyolysis), bilirubin (liver dysfunction), and earlier this year, the removal of ticagrelor during on-pump cardiac surgery, with the goal of reducing costly and potentially fatal perioperative bleeding.
Most recently, Capponi was instrumental in executing the regulatory strategy that led to U.S. Food and Drug Administration Emergency Use Authorization (EUA) of CytoSorb in adult, critically-ill, COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances, and the recent FDA Breakthrough Designation for the removal of ticagrelor during on-pump emergent and urgent cardiothoracic surgery.
In his new role Capponi will continue to oversee the operations of the company, with a strong team reporting to him, but will now focus on the development of new exciting opportunities for CytoSorb and its other technologies.
Last week, CytoSorbents announced a new chief medical officer.